Nordic Nanovector: Promising Results from Preclinical Studies with a Novel CD37-targeted Alpha Therapy for B-cell Tumours to be Presented at ASH

OSLO, Norway, Nov 1, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting promising results from a research collaboration to develop a novel CD37-targeting alpha therapy for B-cell malignancies has been published. The complete results will be...

from PR Newswire: //https://ift.tt/2yIr1A3